In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Survodutide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 172 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 37 (37 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 35 · 10 active1 more mentions it but does not test it | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Survodutide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 30237 | 1,1171067491 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMetabolic and weight | 42384 | 83481717 |
|---|
| Adverse eventsWhole body | 2424 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1212 | 185185 |
|---|
| Liver fat and liver functionLiver | 29281 | 1361279 |
|---|
| LipidsCardiovascular | 22 | 14313733 |
|---|
| Blood pressureCardiovascular | 11 | 1201182 |
|---|
| Inflammation markersKidney and urinary | 11 | 117100152 |
|---|
| Kidney functionKidney and urinary | 66 | 1049932 |
|---|
| Appetite and food intakeNervous system and cognition | 22 | 1129517 |
|---|
| PharmacokineticsPharmacology | 33 | 969231 |
|---|
| Receptor activity and mechanismPharmacology | 185112 | 8250626 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Survodutide differs from Glucagon at 9 positions.
What is different
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 35 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Boehringer Ingelheim5,531 participants20 Nov 2023 to 30 Jun 2026
Obesity
Boehringer Ingelheim1,800 participants14 Oct 2024 to est. 27 Dec 2031
Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
Boehringer Ingelheim1,590 participants12 Nov 2024 to est. 5 Jun 2029
Metabolic Dysfunction Associated Steatohepatitis
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Survodutide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −12.2% Mean body weight change · survodutide 3.6 mg Placebo: −5.4% Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026 | −5.8% Mean weight change · liraglutide 3.0 mg Placebo: −1.5% Dose studied: 3.0 mg56 weeksn = 3962020 |
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in percentage points | −0.9 percentage points HbA1c change · survodutide 3.6 mg Placebo: −0.2 percentage points Dose studied: 3.6 mg once weeklyn not reported2026 | |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 8% Serious adverse events Placebo: 7% Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024 | 6.2% Serious events Placebo: 5% Dose studied: 3.0 mg once daily56 weeks |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 80.9% Gastrointestinal adverse events · survodutide 3.6 mg Placebo: 47.9% Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026 | 82.7% Gastrointestinal adverse events · liraglutide 3.0 mg |
−12.2%
Mean body weight change · survodutide 3.6 mg
Placebo: −5.4%
Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026
−5.8%
Mean weight change · liraglutide 3.0 mg
Placebo: −1.5%
Dose studied: 3.0 mg56 weeksn = 3962020
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Survodutide | Liraglutide |
|---|---|---|
| Liver fat and liver functionLiverCompared as: difference from placebo, in % | No comparable result 15 randomized-trial results measure it in another way or another unit. | −44% Liver fat reduction · Shown as a change. The study reports a liver fat reduction of this size. |
−0.64 percentage points
HbA1c change
Placebo: 0.42 percentage points
Dose studied: up to 1.8 mg per day26 weeksn = 1342019
−0.9 percentage points
HbA1c change · survodutide 3.6 mg
Placebo: −0.2 percentage points
Dose studied: 3.6 mg once weeklyn not reported2026
−0.64 percentage points
HbA1c change
Placebo: 0.42 percentage points
Dose studied: up to 1.8 mg per day26 weeksn = 1342019
8%
Serious adverse events
Placebo: 7%
Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024
6.2%
Serious events
Placebo: 5%
Dose studied: 3.0 mg once daily56 weeksn = 3,7312015
80.9%
Gastrointestinal adverse events · survodutide 3.6 mg
Placebo: 47.9%
Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026
82.7%
Gastrointestinal adverse events · liraglutide 3.0 mg
Dose studied: 3.0 mg once daily68 weeksn = 1272022
| Receptor activity and mechanismCardiovascularCompared as: difference from placebo, in proteins | No comparable result 3 randomized-trial results measure it in another way or another unit. | 124 proteins Proteins modulated Dose studied: 3 mg daily5 weeksn = 202026 |
|---|
| PharmacokineticsPharmacologyCompared as: difference from placebo, in minutes | No comparable result 1 randomized-trial result measure it in another way or another unit. | 15 minutes tmax delay Dose studied: 1.8 mgn = 182011 |
|---|
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in ng/ml | No randomized trial result 1 result from other study designs. | 14.9 ng/ml Serum NGAL difference Dose studied: 3 mg/d52 weeksn = 1272025 |
|---|
| LipidsCardiovascularCompared as: difference from placebo, in lipids | No randomized trial result 2 results from other study designs. | 21 lipids Lipids decreased 26 weeksn = 1022021 |
|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in meals/day | No randomized trial result 2 results from other study designs. | −1 meals/day Meal replacements per day difference Dose studied: 1.2 mg per dayn = 522015 |
|---|
| Kidney functionKidney and urinaryCompared as: difference from placebo, in % | No randomized trial result 6 results from other study designs. | −32% UAER reduction · Shown as a change. The study reports a uaer reduction of this size. Dose studied: 1.8 mg/d12 weeksn = 272017 |
|---|
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | No randomized trial result 1 result from other study designs. | 4 mm Hg Diastolic nocturnal blood pressure difference Dose studied: 1.8 mg once daily24 weeksn = 1002017 |
|---|
No comparable result
15 randomized-trial results measure it in another way or another unit.
−44%
Liver fat reduction · Shown as a change. The study reports a liver fat reduction of this size.
Dose studied: 1.8 mg/d26 weeksn = 722018
No comparable result
3 randomized-trial results measure it in another way or another unit.
124 proteins
Proteins modulated
Dose studied: 3 mg daily5 weeksn = 202026
No comparable result
1 randomized-trial result measure it in another way or another unit.
15 minutes
tmax delay
Dose studied: 1.8 mgn = 182011
No randomized trial result
1 result from other study designs.
14.9 ng/ml
Serum NGAL difference
Dose studied: 3 mg/d52 weeksn = 1272025
No randomized trial result
2 results from other study designs.
21 lipids
Lipids decreased
26 weeksn = 1022021
No randomized trial result
2 results from other study designs.
−1 meals/day
Meal replacements per day difference
Dose studied: 1.2 mg per dayn = 522015
No randomized trial result
6 results from other study designs.
−32%
UAER reduction · Shown as a change. The study reports a uaer reduction of this size.
Dose studied: 1.8 mg/d12 weeksn = 272017
No randomized trial result
1 result from other study designs.
4 mm Hg
Diastolic nocturnal blood pressure difference
Dose studied: 1.8 mg once daily24 weeksn = 1002017